Baseline demographic and disease characteristics
| Characteristic . | N = 221 . |
|---|---|
| Age, median (range), y | 59.0 (21-89) |
| Age group, n (%) | |
| <65 y | 145 (65.6) |
| ≥65 y | 76 (34.4) |
| Gender, n (%) | |
| Female | 73 (33.0) |
| Male | 148 (67.0) |
| Histologic subtype, n (%) | |
| PTCL-NOS | 108 (48.9) |
| AITL | 47 (21.3) |
| ALCL, ALK negative | 26 (11.8) |
| tMF | 12 (5.4) |
| ENKTCL nasal type | 7 (3.2) |
| Blastic NK lymphoma | 4 (1.8) |
| Adult TCL/leukemia HTLV1+ | 2 (0.9) |
| Subcutaneous panniculitis-like TCL | 2 (0.9) |
| Enteropathy-associated TCL | 1 (0.5) |
| Extranodal peripheral NK/T-cell lymphoma unspecified | 1 (0.5) |
| Missing | 11 (5.0) |
| Time from most recent therapy for MTCL, median (range), mo | 2.0 (0.03-89.2) |
| Lines of prior systemic regimens, median (range) | 2.0 (1-14) |
| Number of lines of prior systemic regimens, n (%) | |
| 1 | 76 (34.4) |
| 2 | 60 (27.1) |
| 3 | 38 (17.2) |
| 4 | 20 (9.0) |
| ≥5 | 27 (12.2) |
| R/R at most recent prior therapy,∗ n (%) | |
| Relapsed | 54 (24.4) |
| Refractory | 119 (53.8) |
| Missing | 48 (21.7) |
| Prior treatment for MTCL, n (%) | |
| Chemotherapy | 221 (100.0) |
| SCT | 29 (13.1) |
| Radiation therapy | 49 (22.2) |
| Systemic investigational agents | 7 (3.2) |
| Monoclonal antibody therapy | 3 (1.4) |
| Resection | 2 (0.9) |
| Other therapy | 22 (10.0) |
| Type of prior chemotherapy for MTCL, n (%) | |
| Anthracycline | 198 (89.6) |
| Platinum agents | 90 (40.7) |
| Gemcitabine | 67 (30.3) |
| Methotrexate | 37 (16.7) |
| Novel agents | 27 (12.2) |
| Others | 99 (44.8) |
| Best response to most recent prior regimen, n (%) | |
| CR | 44 (19.9) |
| CRu | 1 (0.5) |
| PR | 39 (17.6) |
| SD | 23 (10.4) |
| PD | 66 (29.9) |
| Not available/not evaluable | 48 (21.7) |
| ECOG performance status, n (%) | |
| 0 | 79 (35.7) |
| 1 | 118 (53.4) |
| 2 | 24 (10.9) |
| Characteristic . | N = 221 . |
|---|---|
| Age, median (range), y | 59.0 (21-89) |
| Age group, n (%) | |
| <65 y | 145 (65.6) |
| ≥65 y | 76 (34.4) |
| Gender, n (%) | |
| Female | 73 (33.0) |
| Male | 148 (67.0) |
| Histologic subtype, n (%) | |
| PTCL-NOS | 108 (48.9) |
| AITL | 47 (21.3) |
| ALCL, ALK negative | 26 (11.8) |
| tMF | 12 (5.4) |
| ENKTCL nasal type | 7 (3.2) |
| Blastic NK lymphoma | 4 (1.8) |
| Adult TCL/leukemia HTLV1+ | 2 (0.9) |
| Subcutaneous panniculitis-like TCL | 2 (0.9) |
| Enteropathy-associated TCL | 1 (0.5) |
| Extranodal peripheral NK/T-cell lymphoma unspecified | 1 (0.5) |
| Missing | 11 (5.0) |
| Time from most recent therapy for MTCL, median (range), mo | 2.0 (0.03-89.2) |
| Lines of prior systemic regimens, median (range) | 2.0 (1-14) |
| Number of lines of prior systemic regimens, n (%) | |
| 1 | 76 (34.4) |
| 2 | 60 (27.1) |
| 3 | 38 (17.2) |
| 4 | 20 (9.0) |
| ≥5 | 27 (12.2) |
| R/R at most recent prior therapy,∗ n (%) | |
| Relapsed | 54 (24.4) |
| Refractory | 119 (53.8) |
| Missing | 48 (21.7) |
| Prior treatment for MTCL, n (%) | |
| Chemotherapy | 221 (100.0) |
| SCT | 29 (13.1) |
| Radiation therapy | 49 (22.2) |
| Systemic investigational agents | 7 (3.2) |
| Monoclonal antibody therapy | 3 (1.4) |
| Resection | 2 (0.9) |
| Other therapy | 22 (10.0) |
| Type of prior chemotherapy for MTCL, n (%) | |
| Anthracycline | 198 (89.6) |
| Platinum agents | 90 (40.7) |
| Gemcitabine | 67 (30.3) |
| Methotrexate | 37 (16.7) |
| Novel agents | 27 (12.2) |
| Others | 99 (44.8) |
| Best response to most recent prior regimen, n (%) | |
| CR | 44 (19.9) |
| CRu | 1 (0.5) |
| PR | 39 (17.6) |
| SD | 23 (10.4) |
| PD | 66 (29.9) |
| Not available/not evaluable | 48 (21.7) |
| ECOG performance status, n (%) | |
| 0 | 79 (35.7) |
| 1 | 118 (53.4) |
| 2 | 24 (10.9) |
ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; ENKTCL, extranodal NK cell/T-cell lymphoma; HTLV, human T-cell leukemia virus; MTCL, mature NK cell and T-cell lymphoma; SD, stable disease; tMF, transformed mycosis fungoides; u, unconfirmed.
Relapsed was defined as on prior therapy achieving a CR or PR lasting for ≥3 months, and refractory was defined as stable disease or PD on prior therapy or relapsed disease <3 months of achieving CR or PR.